If you have multiple myeloma, your healthcare team will conduct further testing to determine the cancer’s stage. Staging refers to the process of determining how advanced a cancer is.

"Anti-GPRC5D CAR T-cell salvage therapy induced a high response rate and might be a potential treatment option in patients with relapsed or refractory multiple myeloma who had pro ...

Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

Real-world data from the University of Catania, Italy, suggest that Pepaxti, a treatment for relapsed, refractory multiple myeloma (RRMM), is effective and well tolerated in heavily pretreated ...

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been ...

opening new possibilities for the use of novel advanced cellular therapies from the mainland in Hong Kong and potentially benefiting a broader range of patients in the future. Myeloma is a ...

A four-drug regimen offers superior disease control and response depth in multiple myeloma compared to three-drug regimens. Adding monoclonal antibodies like Darzalex to standard treatments improves ...

"It is truly encouraging to see how real-world clinical experience continues to confirm the potential of Pepaxti in treating patients with advanced multiple myeloma. Close collaboration with the ...